Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03700567
Other study ID # KY20180713-03
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2018
Est. completion date July 1, 2023

Study information

Verified date November 2023
Source Nanjing First Hospital, Nanjing Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Percutaneous coronary intervention (PCI) has become one of the main treatments for rapid recovery of revascularization in patients with coronary heart disease (CHD). PCI has some advantages, such as easy operation, small trauma and rapid recovery. It can significantly improve myocardial ischemic symptom and reduce the incidence of cardiovascular adverse events in CHD patients. However, many studies have found that the incidence of PCI-related myocardial injury is relatively high, and affect the efficacy of PCI and prognosis in patients with unstable angina pectoris (UAP). A meta-analysis of a total of 7578 patients with UAP from 15 studies who underwent PCI was found to have a 28.7% increase in myocardial biomarkers after PCI. The objective of this randomized control trial is to gain a clinical insight on the use of low temperature contrast for the treatment of PCI-related myocardial injury in UAP patients. The primary objective is assess efficacy and safety of low temperature contrast for the treatment of PCI-related myocardial injury in UAP patients.


Description:

The current study is designed as a multicenter, randomized and prospective study aiming to compare the change in levels of myocardial injury biomarkers (such as TNI and CK-MB) between low temperature contrast group and room temperature contrast group. Based on previous study, the incidence rate of PCI-related myocardial injury is 28.7% in UAP patients undergoing PCI. And in our study the expected incidence rate of PCI-related myocardial injury is up to 14.3% in UAP patients undergoing PCI after treatment with low temperature contrast. Moreover, the investigators estimated 10% loss follow-up of these patients in each arm. As a result, a total of 440 UAP patients were required, and with 220 patients per group as a ratio of 1:1 randomization.


Recruitment information / eligibility

Status Completed
Enrollment 440
Est. completion date July 1, 2023
Est. primary completion date July 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - De novo lesions - Those who meet the diagnostic criteria of unstable angina pectoris - New generation drug eluting stent implantation - Only single coronary artery treated at this time Exclusion Criteria: - Those who meet the diagnostic criteria of acute myocardial infarction - Those who meet the diagnostic criteria of stable angina pectoris - Patients with cardio-genic shock - Patients with multiple organ failure - Patients allergic to contrast - Patients who can not tolerate dual antiplatelet therapy - Patients who can't tolerate anticoagulation - Recently infected patients - Patients with hepatorenal dysfunction - Thrombotic lesion of coronary artery - Chronic total coronary occlusion lesion - Patients with complex coronary bifurcation requiring two stent strategy - Severe coronary calcified lesion - Patients with percutaneous coronary angioplasty - Patients with directional coronary atherectomy or rotational atherectomy - Patients with drug coated balloon treatment - Patients with bioabsorbable vascular scaffold implantation - Previous percutaneous coronary intervention or coronary artery bypass graft - Patients with active stage of autoimmune disease

Study Design


Intervention

Other:
low temperature contrast
UAP patients undergoing PCI were performed with low temperature contrast. The investigators used thermal insulation equipment to keep contrast at 5?. The EKG and blood pressure were monitored during the PCI procedure. After PCI, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.

Locations

Country Name City State
China The First People's Hospital of Changzhou Changzhou Jiangsu
China MingGuang People's Hospital Chuzhou Anhui
China The First People's Hospital of Chuzhou Chuzhou Anhui
China The First People's Hospital of Lianyungang Lianyungang Jiangsu
China Nanjing First Hospital Nanjing Jiangsu
China The Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu
China The People's hospital of Yixing Yixing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Nanjing First Hospital, Nanjing Medical University

Country where clinical trial is conducted

China, 

References & Publications (2)

Moschovitis A, Cook S, Meier B. Percutaneous coronary interventions in Europe in 2006. EuroIntervention. 2010 Jun;6(2):189-94. — View Citation

Testa L, Van Gaal WJ, Biondi Zoccai GG, Agostoni P, Latini RA, Bedogni F, Porto I, Banning AP. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM. 2009 Jun;102(6):369-78. doi: 10.1093/qjmed/hcp005. Epub 2009 Mar 13. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The incidence rate of PCI-related myocardial injury in UAP patients 3 days after PCI the incidence rate of PCI-related myocardial injury indicated by the changes of myocardial injury biomarkers (such as TNI and CK-MB) in UAP patients between low temperature contrast and room temperature contrast groups 3 days after PCI
See also
  Status Clinical Trial Phase
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed NCT02612116 - Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study Phase 4
Active, not recruiting NCT02508714 - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents N/A
Completed NCT02939248 - Influence of Naloxone on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine Phase 4
Active, not recruiting NCT02175706 - DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity N/A
Completed NCT01377402 - ARgentinean Risk Assessment Registry in ACS; the ARRA-RACS Study N/A
Completed NCT00521976 - Risk Markers in the Acute Coronary Syndromes
Completed NCT02144090 - Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study N/A
Completed NCT00627744 - Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction Phase 4
Completed NCT00990262 - Rule Out Myocardial Infarction by Computer Assisted Tomography N/A
Enrolling by invitation NCT04008173 - The International Survey of Acute Coronary Syndromes-ARCHIVES
Withdrawn NCT02165670 - BASIC VALIDATE Coronary Stent Registry
Completed NCT01293097 - Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI Phase 4
Completed NCT01066650 - The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente Phase 4
Completed NCT02747329 - A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT N/A
Completed NCT02939235 - Influence of Metoclopramide on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine Phase 4
Not yet recruiting NCT03155971 - PCB for Long De Novo Lesions of Main Coronary Arteries (D-Lesion Long Trial) N/A
Recruiting NCT04575207 - The Flash FFR Ⅱ Study N/A
Terminated NCT02235753 - High-intensity Exercise After Acute Cardiac Event (HITCARE) N/A
Completed NCT02007187 - Danhong Injection in the Treatment of Unstable Angina Pectoris Phase 4